arrow_back Back Filing freshness 10-Q FY 2024 SEC EDGAR

download Export Data

Clearside Biomedical, Inc.

CLSDQ

— Price unavailable

12 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

Clearside Biomedical, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth -79.8% ↘

Op. Margin None

ROIC 58.7% ↘

FCF / Share $-0.35 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.66M

↓ -79.8% —

Net Income Profit after all expenses

$-34.35M

↓ -5.7% —

Operating Margin Operating profit as % of sales

-302.0%

↓ -14145.9% —

FCF / Share Free cash flow per share

$-0.35

↓ -8.0% —

Long-Term Debt Long-term obligations

$5.00M

↓ -50.0% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue Growth YoY (%)	-79.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1097%)	519.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6399%)	-95.5% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1294%)	274.7% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3333%)	263.3% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3191%)	7143.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+89192%)	-91.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1241%)	—	—	—	—	—
EPS Growth YoY (%)	11.3% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	3.6% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-5.7% Weak Weak Year-over-year change in net income	1.4% Caution Caution Year-over-year change in net income	N/M	N/M	40.8% Excellent ↑ Excellent Improving Year-over-year change in net income	62.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-40.4% Weak ↑ Weak Improving Year-over-year change in net income	-127.9% Weak ↓ Weak Declining Year-over-year change in net income	-46.7% Weak Weak Year-over-year change in net income	-73.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-8.0% Weak ↑ Weak Improving Year-over-year change in free cash flow	-42.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	-23.2% Weak Weak Year-over-year change in free cash flow	35.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-61.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	1.4% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-15.2% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	895.3% Excellent Excellent Compound annual revenue growth over 3 years	183.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	-5.2% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	207.3% Excellent Excellent Compound annual revenue growth over 5 years	30.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Operating Margin (%) (%)	—	-302.0% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2113%)	—	-2.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-114%)	-227.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1615%)	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	-394.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3391%)	—	1.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-89%)	-230.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2022%)	—	—	—	—	—	—	—
FCF Margin (%) (%)	—	-242.1% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	—	-36.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-166.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—
FCF / Net Income (x)	0.75x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-28.55x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	58.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	123.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-225.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-1.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-161.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-148.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-194.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-176.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	23.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	42.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	40.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-114.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-73.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-92.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-113.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-188.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-144.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	27.5% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	-82.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	88.4% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+489%)	204.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1261%)	—	1.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-93%)	-207.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1485%)	-275.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1939%)	—	-275.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1936%)	-36.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-341%)	48.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+221%)	53.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+254%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Debt to Equity (x)	—	—	—	—	—	0.45x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-25%)	0.42x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-29%)	0.22x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-63%)	0.11x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-81%)	-0.12x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-119%)	—	—
Interest Coverage (x)	—	—	—	—	-34.23x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-35.95x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-110.45x Weak Weak Operating income divided by interest expense Optimal: > 5x	-89.45x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-20.02M	$-28.92M	$-48.26M	$-30.44M	$-17.29M	$-17.59M	$1.96M	$-4.42M	$-26.82M	$-16.04M	$-8.27M	$-1.91M
Debt / EBITDA (x)	—	—	—	—	—	-0.17x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.12x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.08x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.34x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.25x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	$0.02	$0.13	$0.02	$0.51	$0.17	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.47	$-0.53	$-0.55	$0.01	$-0.39	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.35	$-0.32	$-0.23	$-0.18	$-0.28	—	—	—	—	—	—	—
Book Value per Share (USD)	$-0.51	$-0.25	$0.17	$0.64	$0.17	$0.25	$0.74	$0.84	$2.92	$-13.79	—	—
Tangible Book Value per Share (USD)	$-0.51	$-0.25	$0.17	$0.64	$0.17	$0.25	$0.74	$0.84	$2.92	$-13.79	—	—
Basic Weighted Avg Shares (shares)	73.80M	61.81M	60.20M	58.49M	46.51M	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Working Capital (USD)	$16.48M	$23.31M	$43.62M	$37.50M	$8.18M	$14.32M	$32.47M	$25.68M	$78.91M	$15.29M	—	—
LT Debt (USD)	—	—	—	—	—	$5.00M	$10.00M	$4.81M	$8.00M	$4.24M	—	—
Total Equity (USD)	$-38.85M	$-15.91M	$10.61M	$37.98M	$8.76M	$11.16M	$23.62M	$21.41M	$71.66M	$-36.66M	$-19.21M	$-10.74M

📋 What is driving earnings? 4 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$1.66M	$8.23M	$1.33M	$29.57M	$7.89M	$2.17M	$30.00K	$345.00K	—	—	—	—
Depreciation Expense (USD)	$226.00K	$67.00K	$145.00K	$178.00K	$180.00K	$211.00K	$189.00K	$182.00K	$65.00K	$60.00K	$33.00K	—
Net Income, GAAP (USD)	$-34.35M	$-32.48M	$-32.95M	$376.00K	$-18.21M	$-30.77M	$-82.82M	$-58.98M	$-25.88M	$-17.64M	$-10.19M	—
Operating Cash Flow (USD)	$-24.70M	$-18.14M	$-13.37M	$-10.73M	$-13.12M	$-27.07M	$-79.20M	$-51.08M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 45 quarters

Clearside Biomedical, Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CLSDQ with peers